Johnson & Johnson

Johnson & Johnson is a global leader in healthcare, focusing on the research, development, manufacturing, and sale of a diverse range of products that include pharmaceuticals, medical devices, and diagnostics. The company is dedicated to improving access to healthcare and fostering healthier communities. In addition to its core business, Johnson & Johnson also engages in initiatives that support purpose-driven entrepreneurs who are innovating at the forefront of care, demonstrating its commitment to advancing health and well-being on a broader scale.

Alex Gorsky

Chairman and CEO

Neville L. Johnson

Partner

Sandra Peterson

Group Worldwide Chairman

Todd M. Pope

Global President Cordis Corporation

Tim Schmid

Executive Vice President, Worldwide Chairman, MedTech

85 past transactions

CareLoop Health

Seed Round in 2025
CareLoop, an innovation emerging from the University of Manchester, furnishes patients with digital support resources while simultaneously providing healthcare professionals with the means to monitor and track patient symptoms.

Intra-Cellular Therapies

Acquisition in 2025
Intra-Cellular Therapies, Inc. is a biopharmaceutical company based in New York that focuses on developing innovative treatments for neuropsychiatric and neurologic diseases, as well as other central nervous system (CNS) disorders. The company’s lead drug candidate, CAPLYTA, is designed to treat schizophrenia and bipolar disorder, along with behavioral disturbances associated with dementia and autism. Additionally, Intra-Cellular Therapies is working on several other drug candidates, including ITI-002, which targets phosphodiesterase type 1; ITI-214 for Parkinson’s disease; and ITI-333 for substance use disorders, pain, and related psychiatric conditions. The company employs a multidisciplinary approach that combines the expertise of medicinal scientists, pharmacologists, and clinical development scientists to create novel therapies. Intra-Cellular Therapies also utilizes its CNSProfile technology platform to generate molecular signatures for drug compounds, aiding in drug discovery and development, and has engaged in collaborations to investigate antidotes for chemical warfare agents.

Alessa Therapeutics

Seed Round in 2024
Alessa Therapeutics, Inc. is a pre-clinical stage biotechnology company based in San Francisco, California, focused on developing localized treatments for solid organ diseases. Founded in 2018, the company specializes in a drug delivery implantable system specifically designed to treat prostate cancer. This innovative system allows for the sustained and localized administration of anti-androgen drugs directly to the tumor in the prostate, minimizing systemic exposure and enhancing treatment efficacy. By concentrating on localized therapies, Alessa Therapeutics aims to improve patient outcomes in the management of various organ diseases.

Tempo Therapeutics

Venture Round in 2024
Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine. It provides power to regenerative medicine, providing materials that evade the typical host immune rejection response to build synthetic tissue hybrids from skin to bone to heart to brain.

V-Wave

Acquisition in 2024
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Yellow Jersey Therapeutics

Acquisition in 2024
Yellow Jersey Therapeutics provides pharmaceutical therapeutic and medical services.

Proteologix

Acquisition in 2024
Proteologix is a precision immunology company powered by proprietary multi-specific antibody technologies. The company is dedicated to the discovery and development of safe and convenient therapeutics that target multiple disease-driving pathways to potentially deliver high-bar efficacy for patients with immune-mediated diseases.

Hamilton Health Box

Series A in 2024
Hamilton Health Box operates onsite direct primary and urgent care microclinics tailored for self-insured employers. The company focuses on making healthcare accessible, convenient, and affordable, ensuring that care is delivered when and where it is needed. Hamilton Health Box employs a hybrid primary care model that caters to small employers and rural populations, fostering healthier communities while aiming to reduce overall healthcare costs. With a dedicated team of healthcare professionals, the company provides comprehensive care for employees and their families, acting as a reliable partner in managing their health needs.

Johnson & Johnson

Acquisition in 2024
Johnson & Johnson is a global leader in healthcare, focusing on the research, development, manufacturing, and sale of a diverse range of products that include pharmaceuticals, medical devices, and diagnostics. The company is dedicated to improving access to healthcare and fostering healthier communities. In addition to its core business, Johnson & Johnson also engages in initiatives that support purpose-driven entrepreneurs who are innovating at the forefront of care, demonstrating its commitment to advancing health and well-being on a broader scale.

Ambrx

Acquisition in 2024
Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Health In Her HUE

Seed Round in 2024
Health In Her HUE is a digital platform aimed at connecting Black women and women of color with culturally sensitive healthcare providers. The platform offers access to evidence-based health content that resonates with the cultural experiences of these communities. By leveraging technology, media, and community support, Health In Her HUE seeks to address and reduce racial health disparities, ultimately improving health outcomes for Black women. It provides a space for these women to comfortably engage with healthcare providers and fosters better communication within their communities regarding health matters.

54 Collective

Venture Round in 2023
54 Collective is a venture capital firm based in Johannesburg, South Africa, founded in 2018. The company focuses on building and scaling African tech startups by providing catalytic capital and tailored support to entrepreneurs. It invests primarily in sectors such as fintech, health tech, agritech, logistics, and e-commerce. By integrating impact into its investment strategy, 54 Collective aims to deliver financial returns to investors while facilitating the growth of innovative businesses. The firm leverages its extensive global network to offer additional resources and support, helping founders navigate challenges and scale their ventures effectively.

Mamotest

Seed Round in 2023
Mamotest is a technology-driven company focused on improving breast cancer outcomes through early diagnosis and patient guidance. By leveraging artificial intelligence, Mamotest has developed a collaborative platform that democratizes access to screening and diagnosis, facilitating an efficient path to treatment. The company's innovative approach integrates telediagnosis and ensures complete traceability of the patient journey, aiming to transition healthcare from a reactive model to one that prioritizes prevention and health maintenance. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates, thereby enhancing the overall quality of care for patients.

SwipeRx

Series B in 2023
SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Abiomed

Acquisition in 2022
Abiomed is a company that specializes in mechanical circulatory support devices aimed at assisting heart failure patients. It develops, manufactures, and markets products designed to improve blood flow and temporarily aid the heart's pumping function, allowing the organ to rest, heal, and recover. Its devices are primarily utilized in cardiac catheterization labs by interventional cardiologists and in surgical settings by heart surgeons. These products are essential for patients requiring hemodynamic support before, during, or after procedures such as angioplasty and heart surgery. A significant portion of Abiomed's revenue is generated from its Impella product portfolio, which includes advanced percutaneous micro heart pumps equipped with integration motors and sensors.

SwipeRx

Series B in 2022
SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

IndyGeneUS AI

Grant in 2021
IndyGeneUS AI is a Black-Owned and Service-Disabled Veteran-Owned Small Business specializing in genomics. The company is developing the world's largest blockchain-encrypted repository of clinical and genomic data specifically for indigenous and diasporic African populations. Utilizing proprietary technology, IndyGeneUS AI integrates multi-omics data, electronic healthcare records, and scientific literature to identify novel signature sequences, biomarkers, and polygenic risk scores. This extensive data repository aims to enhance disease prevention, detection, and drug discovery while promoting clinical disease management and precision health equity. By focusing on the unique genomic characteristics of these populations, the company seeks to improve the efficiency and quality of healthcare delivery.

Lucia Health Guidelines

Grant in 2021
Lucia Health Guidelines develops a clinical decision support tool that utilizes cloud computing and machine learning to enhance adherence to clinical guidelines at the point of care. The primary focus of the company's platform is to improve the diagnosis and treatment of Atrial Fibrillation (AFib) within Emergency Departments. By providing clinicians with effective tools to accurately identify AFib, the technology facilitates the initiation of guideline-recommended treatments aimed at preventing strokes. This approach not only aims to save lives and improve patient outcomes but also seeks to lower overall healthcare costs by promoting adherence to established medical recommendations.

Ayana Therapy

Seed Round in 2021
Ayana Therapy is a telehealth platform dedicated to providing mental health services to marginalized and intersectional communities. By utilizing a smart matchmaking algorithm, the platform connects users with licensed therapists who share an understanding of their cultural backgrounds and identity traits, including race, gender identity, class, sexuality, and ethnicity. Ayana Therapy aims to address the significant barriers faced by people of color and LGBTQ+ individuals in accessing mental health care, such as high costs, stigma, and a lack of cultural competency within the healthcare system. The platform fosters a user-friendly environment that offers a safe space for individuals whose voices have been historically dismissed or neglected, ensuring that they receive the mental health support they need.

Radical Health

Seed Round in 2021
Radical Health is a healthcare technology company focused on promoting health equity through meaningful conversations and community engagement. By leveraging AI-enabled technology, Radical Health helps individuals better understand their health during medical visits, fostering trust and self-advocacy. The company offers workshops and training that facilitate deeper discussions around the social determinants of health for both community members and healthcare providers. In addition, Radical Health features Radical Relay, an AI-based chat application designed to empower individuals with knowledge of their rights throughout pregnancy. Through its innovative approach, Radical Health aims to equip and empower people to actively advocate for themselves within the healthcare system.

TQIntelligence

Venture Round in 2021
TQIntelligence, Inc. operates a platform that measures emotional distress severity through voice-based artificial intelligence technology. Founded in 2016 and headquartered in Atlanta, Georgia, the company integrates various data sources to provide cognitive insights into risk stratification, treatment outcomes, and personalized behavioral health interventions. Its key products include TQ-Intelligence, which utilizes voice and speech analytics alongside psychometrically sound instruments, and TQ Analytics, which leverages existing electronic medical record data to deliver actionable insights. TQIntelligence's machine learning analytics and real-time prediction capabilities support therapists in diagnosing mental health issues, particularly for children and adolescents, including those from BIPOC and LGBTQ communities. By focusing on voice biomarkers, the company aims to enhance treatment planning and reduce care costs while improving outcomes in the behavioral healthcare sector.

Patient Orator

Seed Round in 2021
Patient Orator is a mental health company that focuses on enhancing communication between marginalized communities and healthcare providers through its mobile application. The platform utilizes storytelling to create a safe digital environment where users can openly discuss their health concerns and social needs without fear of judgment or bias. By emphasizing preventative medicine and shared decision-making, Patient Orator aims to improve patient experiences and overall population health. The application is designed to ensure that individuals from diverse backgrounds, regardless of race, ethnicity, gender, nationality, or insurance status, have better access to essential healthcare resources.

Momenta Pharmaceuticals

Acquisition in 2020
Momenta Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of innovative therapeutics for rare immune-mediated diseases. The company's product pipeline includes novel therapeutics such as M281, a fully-human monoclonal antibody targeting the neonatal Fc receptor to reduce circulating IgG antibodies; M254, aimed at treating inflammatory diseases; and M230, a recombinant trivalent IgG1 Fc multimer designed for enhanced therapeutic activity. Additionally, Momenta has developed complex generic products, including M-Enoxaparin, a generic version of Lovenox, and M356, a generic of Copaxone for multiple sclerosis. Momenta also has biosimilar programs, including M923, a biosimilar of HUMIRA, and M710, a biosimilar of EYLEA for various eye conditions. Despite previously pursuing the generics and biosimilars market, the company shifted its focus to innovative drug development, with several promising candidates in the pipeline for autoimmune diseases. Momenta was founded in 2001 and operates as a subsidiary of Johnson & Johnson.

TARIS Biomedical

Acquisition in 2019
TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Verb Surgical

Acquisition in 2019
Verb Surgical Inc. is a company that develops a digital surgery platform aimed at transforming surgical procedures. Established in 2015 and headquartered in Santa Clara, California, the company focuses on integrating robotics, advanced visualization, sophisticated instrumentation, data analytics, and connectivity to enhance the capabilities of operating room professionals. By leveraging these technologies, Verb Surgical seeks to improve patient outcomes and reduce the overall cost of care, making surgical procedures more accessible and efficient. As a subsidiary of Johnson & Johnson Innovation - JJDC, Inc., Verb Surgical aims to democratize surgery through its innovative platform.

knowRX Health

Pre Seed Round in 2019
KnowRX is a developer of a cloud-based digital healthcare platform designed to enhance therapeutic care by facilitating patient and physician engagement. The platform employs machine learning technology, known as Maestro ML™, to create personalized care pathways that support clinical trial participation, improve medication adherence, and promote daily wellness activities across nutritional, psychological, and physical domains. It provides healthcare providers and patients with critical drug information, current clinical trial updates, and resources for selecting appropriate therapies. Additionally, the platform offers access to counseling, genomic data for treatment compatibility, nutritional guidance, and instructional content on clinical research. By streamlining communication between patients and healthcare professionals, KnowRX aims to optimize treatment outcomes and empower patients in their self-care journeys.

M-Scan

Grant in 2019
M-Scan is a medical device company focused on developing portable mobile ultrasound devices specifically designed for pregnant mothers. The company aims to improve maternal and neonatal health by leveraging smart device technology to facilitate early detection and management of risks associated with maternal and neonatal mortality. By providing these innovative ultrasound solutions, M-Scan seeks to enhance the quality of life for mothers and their children, particularly in resource-limited settings where access to traditional healthcare may be challenging.

Tiny Hearts

Grant in 2019
Tiny Hearts provides production and deployment of phototherapy treatment essentials, procurement and supply of other medical equipment and disposables to hospitals. Their customers inquiries are addressed through phone, email, and online applications.

Uganics

Grant in 2019
Uganics is an organization providing organic mosquito repellent products including soaps, candles, lotion bars, and essential oils. Uganics produces an affordable and long-lasting organic mosquito repellent soap that helps mothers with children below the age of five in rural communities to prevent mosquito bites.

DayTwo

Series B in 2019
DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Oncochain

Non Equity Assistance in 2019
Oncochain is focused on creating a real-world data platform tailored for oncology, aimed at standardizing and aggregating anonymized data from cancer patients. This platform generates valuable analytics that support pharmaceutical research and enhance value-based care for healthcare providers. Utilizing a web-based oncology-specific electronic health record, Oncochain develops operational data repositories that streamline the information flow between providers and enhance the skills of oncology professionals. The platform significantly aids research by reducing the time required for patient recruitment in clinical trials and establishing a framework for multi-centric study design and implementation. Through its SaaS analytics tool, Oncochain provides critical real-world data insights to clients, including pharmaceutical companies and contract research organizations, ultimately contributing to improved outcomes in oncological care and accelerating research efforts.

Auris Health

Acquisition in 2019
Auris Health, Inc., based in Redwood City, California, develops innovative robotic technology for medical applications, particularly in the field of endoscopy. The company is known for its Monarch Platform, which facilitates diagnostic and therapeutic bronchoscopic procedures by utilizing small cameras and tools that access the body through natural openings. In addition to endoscopic applications, Auris Health is creating a novel dual-arm microsurgical system aimed at enhancing ophthalmic surgery. By integrating advancements in imaging technology, robotics, micro-instrumentation, and data science, Auris Health seeks to transform medical interventions, ultimately improving patient outcomes and reducing costs. Founded in 2007, the company operates as a subsidiary of Johnson & Johnson.

CI:Z Holdings

Acquisition in 2018
Ci:z Holdings Co., Ltd. is a Japan-based company engaged in the development, manufacturing, and sale of cosmetics, health foods, and beauty care products. Founded in 1999 and headquartered in Tokyo, the company operates primarily through two segments: cosmetics and health food. The cosmetics segment includes a diverse range of products designed for various skin issues, featuring brands such as Dr.Ci:Labo, Labo Labo, and Genomer, which contribute significantly to the company's revenue. The health food segment offers nutritional supplements and other products aimed at enhancing health and beauty from within. Ci:z Holdings distributes its products through mail order, wholesale channels, and directly operated stores, as well as through retail outlets such as drug stores and department stores, both in Japan and internationally.

Zarbee's

Acquisition in 2018
Zarbee's, Inc. is a health-focused company that manufactures and sells a range of products designed for cough and throat relief, immune support, and general wellness, including vitamins and supplements for both children and adults. Founded in 2007 and headquartered in Draper, Utah, Zarbee's aims to provide clinically proven, natural health solutions for families. The company distributes its products through various retail channels, both in physical stores and online. Additionally, Zarbee's has a location in Greenwich, Connecticut, and operates as a subsidiary of Johnson & Johnson Consumer Inc.

Cue

Series B in 2018
Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Dreem

Venture Round in 2018
Dreem is a neurotechnology company building consumer technology that stimulates the brain to enhance human potential. The company's product, Dreem is a wearable device that enhances the quality of deep sleep. The device monitors brainwaves, analyzes user's sleep and stimulates the brain with sound in order to extend the amount of deep sleep, improving human performance throughout the day.

Orthotaxy

Acquisition in 2018
Orthotaxy is a medical technology company based in Gières, France, specializing in software-enabled surgery solutions for the healthcare industry. The company focuses on designing and developing computer-assisted platforms that enhance surgical procedures. With a team of qualified engineers, Orthotaxy creates innovative medical devices that are subject to rigorous quality assurance processes. This approach allows healthcare providers to personalize surgical procedures and optimize outcomes for patients.

Bloomlife

Grant in 2018
Bloomlife is a women's health company focused on addressing critical challenges in maternal health through an innovative remote care platform. By integrating connected devices with cloud-based data analytics, Bloomlife enhances access to care and empowers expectant mothers while providing clinicians with essential information to better screen and manage pregnancy complications. The company's prenatal wearable technology is designed to assess fetal health, enabling the identification of potential complications that could lead to serious outcomes such as brain damage or stillbirth. This approach marks a significant departure from traditional methods of managing high-risk pregnancies, which often involve frequent in-person appointments and lengthy referral processes. Bloomlife aims to be a leader in remote maternal care, facilitating timely interventions and support for women, regardless of geographic barriers.

Prapela

Grant in 2017
Prapela is a company that offers noninvasive stimulation therapy designed to enhance the health of newborns, specifically targeting issues such as irregular breathing and low oxygenation. By placing a reusable pad inside a hospital bassinet or incubator, Prapela provides gentle stimulation that supports the natural processes of breathing control and oxygenation. This therapy aims to improve cardiorespiratory outcomes while reducing the need for pharmacotherapy and minimizing the duration of conventional treatments for severe medical conditions. Since its inception, Prapela has garnered significant recognition as a leading pediatric medical device startup, receiving multiple awards and over $8 million in grants. The company collaborates with neonatologists, the National Institutes of Health, and the FDA to develop and refine its solutions, contributing to better health outcomes for newborns.

DayTwo

Series A in 2017
DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Actelion Pharmaceuticals

Acquisition in 2017
Actelion Ltd is a Swiss biopharmaceutical company dedicated to the discovery, development, and commercialization of low molecular weight drugs aimed at addressing various medical conditions. The company's primary focus is on pulmonary arterial hypertension (PAH), offering several treatments including Tracleer, Opsumit, Uptravi, Ventavis, and Veletri, each designed to target different stages of the disease through various administration methods. Additionally, Actelion markets Zavesca, an oral treatment for type 1 Gaucher disease, and Valchlor, which is indicated for a rare form of blood cancer. Established in 1997 and headquartered in Allschwil, Switzerland, Actelion has developed a robust global commercial infrastructure for its orphan drugs and actively enhances its product pipeline through in-licensing and acquisitions. The company also collaborates with Merck & Co., Inc. to explore new classes of renin inhibitors for cardio-renal diseases, reflecting its commitment to addressing a wide range of health challenges, including cardiovascular, immunological, infectious, metabolic, and central nervous system disorders.

RayIoT Solutions

Convertible Note in 2017
RayIoT is a platform consisting of devices and software to enable health monitoring in the native environment of the user. Powered by AI, our solutions help in predictive analysis of health conditions. With algorithms having an accuracy of 98% with close to 500 hours of clinical evaluation, you can now access clinical grade performance at the comfort of your home. The connected and comprehensive workflow helps in early detection of abnormal variations in vitals to management of alerts. rayIoT aims to facilitate decision making on health conditions by exploring potential of continuous monitoring of vitals, predominantly breathing rate.

Neurotrack

Grant in 2016
Neurotrack is a digital health company focused on transforming the diagnosis and management of Alzheimer's and other dementias. Founded in 2012 by Elli Kaplan and neuroscientist Dr. Stuart Zola, the company is headquartered in Redwood City, California. Neurotrack develops user-friendly, clinically validated cognitive assessments that can be administered in clinical settings or at home, allowing for early detection of cognitive impairment and ongoing monitoring of cognitive function. The company's solutions are designed to fit seamlessly into various workflows, enabling healthcare providers to efficiently screen patients for cognitive decline and take necessary next steps. Neurotrack has published 27 peer-reviewed papers, holds 11 patents for its proprietary technology, and is registered as an FDA Class II medical device.

Abbott

Acquisition in 2016
Abbott is a global healthcare company focused on advancing health and well-being through a diverse array of products. The company manufactures and markets cardiovascular devices, diabetes management solutions, nutritional products for both adults and children, and diagnostic tools. Notable offerings include pacemakers, implantable cardioverter defibrillators, continuous glucose monitors, and a wide range of branded generic pharmaceuticals. Abbott is also a leader in molecular diagnostics, providing innovative technologies for disease diagnosis, therapy selection, and disease monitoring, with a strong portfolio of over 350 products. Headquartered in Mumbai, Abbott India Limited, a subsidiary of Abbott Laboratories, plays a significant role in providing high-quality medicines across various therapeutic areas such as women's health, cardiology, and gastroenterology. Approximately 60% of Abbott's sales come from international markets, reflecting its extensive global reach and commitment to enhancing health outcomes worldwide.

CI:Z Holdings

Post in 2016
Ci:z Holdings Co., Ltd. is a Japan-based company engaged in the development, manufacturing, and sale of cosmetics, health foods, and beauty care products. Founded in 1999 and headquartered in Tokyo, the company operates primarily through two segments: cosmetics and health food. The cosmetics segment includes a diverse range of products designed for various skin issues, featuring brands such as Dr.Ci:Labo, Labo Labo, and Genomer, which contribute significantly to the company's revenue. The health food segment offers nutritional supplements and other products aimed at enhancing health and beauty from within. Ci:z Holdings distributes its products through mail order, wholesale channels, and directly operated stores, as well as through retail outlets such as drug stores and department stores, both in Japan and internationally.

Vogue International

Acquisition in 2016
Vogue International is one of America’s manufacturer and distributor of salon-heritage hair care and other personal care products. For over 20 years, Vogue has represented a refreshing and innovative point of difference in a saturated hair care industry. Headquartered in Tampa Bay, Florida, Vogue’s branded products include the FX™ line of hair styling products, the award winning OGX® collection of shampoos, conditioners and styling/treatment items, and OGX® Bath & Body Collection. Vogue’s products are distributed exclusively to the world’s largest retailers, primarily through the Food, Drug, and Mass channels of distribution, both domestically throughout the U.S. and globally in 42 foreign countries. The FX™ line of styling products has been an industry leader in new innovation and state of the art technology and continues its amazing success after thirteen years of representation. FX™ is one of America’s top salon inspired brands. Each FX™ product is enriched with the best ingredients, specially selected to give your hair the care it needs to look sexy, styled and healthy every day. OGX® Hair Care is an award-winning collection of over 70 items containing shampoos, conditioners and styling/treatment products, which have been met with rave reviews by retailers and consumers alike. OGX® products contain exotic ingredients and are do not contain Sodium Laureth Sulfate or Sodium Laurel Sulfate …plus the fragrances are amazing! As the leader in the segment, OGX® furthered its commitment by jumping to the forefront of “green” packaging by being the first in the segment to change to environmental friendly components. Our philosophy of “beauty pure and simple” continues with the introduction of a luxurious Bath & Body Collection, this exotic new assortment of creamy lotions, lathering body washes, and an extra hydrating dry body oil feature an amazing moisturizing formulas AND… with a scent for everyone, the Bath & Body Collection provides the perfect complement to Their hair care favorites. “They are constantly recreating the company so They are always offering innovative products to a very savvy consumer,” states Todd Christopher, Vogue’s Founder. “Customers can always look to us for the most advanced beauty products on the market today”, continued Christopher. Through a strong management team, a unique blend of innovation, creativity, technology, skilled dedicated employees, and strong processes, Vogue is able to consistently set the standard of introducing exciting new products that are inherently in touch with the consumers’ demand for salon quality, innovation, and performance, while creating and identifying current and emerging trends.

Suncayr

Grant in 2016
Suncayr has developed a colour changing sticker that tells you when your sunscreen is no longer protecting you. The sticker, "SPOT", is is put directly on the skin, and then sunscreen is applied to your whole body. When your sunscreen is protecting your skin from UV, the sticker is clear, but when your skin becomes exposed to UV, the sticker changes to purple. This will give you and your family the confidence to safely enjoy the sun!

TESARO

Post in 2016
Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Novira Therapeutics

Acquisition in 2015
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on the discovery and development of antiviral drugs targeting chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. Founded in 2006, the company specializes in creating first-in-class oral therapeutics that inhibit the viral capsid, offering innovative treatment options both as standalone therapies and in combination with existing treatments. Novira's antiviral drugs aim to address significant limitations associated with current therapies for chronic HBV and HIV, particularly the challenges of drug resistance and the need for lifelong treatment. By employing a novel mechanism of action, Novira Therapeutics seeks to provide more effective and potentially curative solutions for these global health issues. As of December 2015, Novira operates as a subsidiary of Johnson & Johnson.

NeoStrata Company

Acquisition in 2015
NeoStrata Company, Inc., based in Princeton, New Jersey, develops and markets a wide variety of therapeutic and cosmetic dermatological products. Founded in 1988, the company is renowned for its innovative use of alpha hydroxy acid technology, which was pioneered by its founders, Drs. Van Scott and Yu, who demonstrated the significant benefits of these acids for skin rejuvenation. NeoStrata's product portfolio includes anti-aging systems, concealing treatment cosmetics, and topical solutions for various skin conditions such as psoriasis, acne, and hyperpigmentation. The company's offerings encompass cleansers, toners, moisturizers, serums, and specialized kits, catering to diverse skin types and concerns. NeoStrata products are distributed globally through consumer outlets, medical professionals, pharmacies, and beauty retailers, reflecting its commitment to providing clinically-proven skincare solutions. The company also operates as a subsidiary of Johnson & Johnson Consumer Inc.

Inter-Grosshandel GmbH

Non Equity Assistance in 2015
Inter-Grosshandel offers wide range of wholesale brand clothing

X01

Acquisition in 2015
U.K.-based cardiovascular drug startup

Jagdale industries

Acquisition in 2014
Jagdale Industries Pvt Ltd(JIPL) is a part of the well-established and one-of-the-oldest industrial family group of Bengaluru: ‘The Jagdale family’. The roots of Jagdale go back to 1939 when Associated Drugs Company Ltd., was set up and to the contributions of Late Shri. Radhakrishna Jagdale, founder Jagdale group. JIPL has pioneered several products including unique food, beverage, nutraceutical and pharmaceutical formulations, in line with the nation’s needs and market requirements.

Alios BioPharma

Acquisition in 2014
Alios BioPharma is focused on the discovery and development of innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company employs a range of proprietary technologies, including small molecule activators that stimulate innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons. These complementary platforms enable the development of various therapeutic products targeting serious viral infections, such as chronic hepatitis B and C, HIV, respiratory viruses like pandemic influenza, and emerging viral diseases such as SARS. Alios BioPharma’s unique chemical library of nucleoside analogs and advanced virology-based screening systems further enhance its ability to create effective antiviral agents.

DePuy Synthes

Acquisition in 2014
DePuy Synthes is a leading manufacturer of orthopedic and medical technology equipment focused on enhancing patient recovery and mobility. The company produces a wide range of products designed for various specialties, including joint reconstruction, trauma, craniomaxillofacial surgery, spinal surgery, and sports medicine. Its offerings encompass surgical implants and biomaterials for fixation and orthopedic procedures, including systems for clavicle and olecranon plates, spinal solutions, and advanced surgical tools. Additionally, DePuy Synthes provides comprehensive services, such as advanced case management, loaner programs, and personalized solutions through its Trumatch platform. The company is dedicated to improving surgical outcomes and patient care through innovative products and services.

Aragon Pharmaceuticals

Acquisition in 2013
Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Elsker

Acquisition in 2013
Elsker provides products to care for the skin health of babies. They provide body wash, shampoo, clothes, and talcum powder for babies. They also offer products for pregnant mothers.

Calibra Medical

Acquisition in 2012
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

SterilMed

Acquisition in 2011
SterilMed is a contracting manufacturer specializing in the reprocessing, remanufacturing, and repair of medical devices and equipment. The company offers refurbishing services for a range of medical equipment, including flexible endoscope systems, power equipment, and surgical instruments. SterilMed serves over 1,700 healthcare facilities across North America, providing essential services that extend the lifecycle of medical devices while ensuring compliance with safety and quality standards. Through its focus on sustainability and cost-effectiveness, SterilMed plays a significant role in the healthcare industry by enabling facilities to maintain high-quality standards while managing operational costs.

Crucell

Acquisition in 2011
Crucell N.V. is a global biopharmaceutical company dedicated to the research, development, production, and marketing of vaccines, proteins, and antibodies aimed at preventing and treating infectious diseases. The company offers a diverse portfolio of vaccines, including those for hepatitis B, a fully-liquid vaccine for five key childhood diseases, and a virosome-adjuvanted vaccine for influenza. Additionally, Crucell markets travel vaccines, featuring the only oral anti-typhoid vaccine, an oral cholera vaccine, and the sole aluminum-free hepatitis A vaccine available. Its products are distributed in both public and private markets worldwide, reflecting its commitment to combating infectious diseases through innovative solutions.

Micrus Endovascular Corporation

Acquisition in 2010
Micrus Endovascular Corporation develops and manufactures both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus Endovascular develops products that can be used by interventional neuroradiologists, interventional neurologists, and endovascularly trained neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. The Micrus Endovascular product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. It also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires, and accessory products used in conjunction with its microcoils. Micrus Endovascular Corporation wasfounded in 1996 and is based in San Jose, California. As of September 27, 2010, Micrus Endovascular LLC operates as a subsidiary of Codman & Shurtleff, Inc.

Acclarent

Acquisition in 2009
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

Crucell

Post in 2009
Crucell N.V. is a global biopharmaceutical company dedicated to the research, development, production, and marketing of vaccines, proteins, and antibodies aimed at preventing and treating infectious diseases. The company offers a diverse portfolio of vaccines, including those for hepatitis B, a fully-liquid vaccine for five key childhood diseases, and a virosome-adjuvanted vaccine for influenza. Additionally, Crucell markets travel vaccines, featuring the only oral anti-typhoid vaccine, an oral cholera vaccine, and the sole aluminum-free hepatitis A vaccine available. Its products are distributed in both public and private markets worldwide, reflecting its commitment to combating infectious diseases through innovative solutions.

Cougar Biotechnology

Acquisition in 2009
Cougar Biotechnology, Inc

Omrix Biopharmaceuticals

Acquisition in 2008
Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets biological products for the biosurgical and immunotherapy markets.

HealthMedia

Acquisition in 2008
Founded in 1998 by Dr. Victor Strecher, HealthMedia specializes in developing scalable behavior change interventions that emulate the effectiveness of health coaching without the need for a live coach. The company creates innovative programs tailored for health and wellness, disease management, behavioral health, and medication compliance. HealthMedia collaborates with pharmaceutical firms and medical device manufacturers to address various health challenges, including drug and alcohol addiction, mental illness, cardiovascular diseases, hypertension, and HIV/AIDS. Through its unique methodology and technology, HealthMedia delivers impactful outcomes comparable to traditional health coaching, making it a leader in the field of digital health solutions.

Beijing Dabao Cosmetics

Acquisition in 2008
Beijing Dabao Cosmetics Co., Ltd. is a manufacturer based in Beijing, China, specializing in herbal cosmetic products. The company is involved in the development, production, sale, and export of a diverse range of items, including face wash, moisturizers, sunscreens, shampoos, and various other skincare products. Dabao aims to cater to both domestic and international markets, focusing on the growing demand for herbal and natural cosmetics.

Conor MedSystems

Acquisition in 2007
Conor MedSystems develops innovative controlled vascular drug delivery technologies. They have initially focused on the development of drug eluting stents to treat coronary artery disease.

InnerPulse

Venture Round in 2007
InnerPulse, Inc. develops technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias. It offers invasive treatment that enables physicians to implant the life-saving Percutaneous Implantable Cardioverter Defibrillator within the patient's vascular system. InnerPulse, Inc. was formerly known as Interventional Rhythm Management, Inc.

CardioMEMS

Series D in 2006
CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Groupe Vendome SA

Acquisition in 2006
Groupe Vendome SA manufactures adult and baby skin care products.

Peninsula Pharmaceuticals

Acquisition in 2005
Peninsula Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the licensing, development, and commercialization anti-infective therapies for the treatment of patients with life-threatening infections for the North American and European markets. Peninsula's lead product candidate, doripenem, is a broad-spectrum antibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six Phase III clinical trials. In addition, doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP). Peninsula Pharmaceuticals was acquired by Johnson & Johnson, a global manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. Peninsula Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections.

Transform Pharmaceuticals

Acquisition in 2005
Transform Pharmaceuticals was a pharmaceuticals company specializing in the discovery of improved formulations and novel crystalline forms of drug molecules. Transform’s product portfolio included Topiramate, an anti-epileptic drug. The company was acquired by Johnson & Johnson in 2005. The company was founded in 1998.

3-Dimensional Pharmaceuticals

Acquisition in 2003
3-Dimensional Pharmaceuticals is a drug discovery company that develops advanced technologies to enhance and expedite the drug discovery process. By integrating high-throughput screening, combinatorial chemistry, and structure-based design, the company leverages genome sequencing targets to create efficient and innovative drug discovery solutions.

Topspin Medical

Series B in 2002
TopSpin Medical developed an innovative and unique technology for high-resolution MRI using an IntraVascular MRI (IVMRI) catheter for the coronary arteries, without the need for an expensive and bulky external MRI setup. The catheter contains those components, which are usually found in a conventional MRI scanner, only that they are miniaturized to less than 2 millimeters in size.

Tibotec

Acquisition in 2002
Tibotec is a biopharmaceutical company focused on developing anti-viral treatments, with several promising compounds in development for the treatment of infectious diseases including HIV.

LXN Corporation

Acquisition in 2001
LXN Corporation is a medical technology company that develops, manufactures, and markets products to help people with diabetes better manage their disease. The company offers GlucoProtein, a home-based test that measures overall glucose control. It allows patients and healthcare professionals to better monitor the overall effectiveness of diabetes treatments and make timely and effective therapy changes. LXN Corporation was founded in 1994 and is based in San Diego, California.

BabyCenter

Acquisition in 2001
BabyCenter is a digital parenting platform and subsidiary of Johnson & Johnson, dedicated to providing information and support for parents and parents-to-be throughout the journey of parenthood. The website offers resources on conception, pregnancy, childbirth, and early childhood, catering to the diverse needs of families. Alongside its companion site, ParentCenter, which focuses on children aged 2 to 8, BabyCenter helps users navigate parenting challenges with various tools, including pregnancy calendars, baby name finders, and due date calculators. The platform features buying guides and product comparisons to assist parents in making informed purchasing decisions, and it also includes an online store for direct merchandise purchases. Additionally, BabyCenter fosters a community atmosphere with bulletin boards, chat sessions, and Q&A features, allowing expectant mothers and new parents to connect with peers and medical professionals. Recognized for its excellence, BabyCenter won the Best Family and Parenting Site award at the 2006 Webby Awards.

SAND

Angel Round in 2000
SAND manufactures and sells financial POS machines.

Aveeno

Acquisition in 1999
Aveeno provides skin & hair care products made with the most effective ingredients.

MicroMass Communications

Venture Round in 1998
MicroMass Communications is a marketing agency that specializes in healthcare communications, emphasizing evidence-based behavior change strategies to enhance patient health outcomes. Following the merger of SPS and MicroMass, it has emerged as one of the largest independent, full-service healthcare marketing and medical communications agencies in the Southeast. The agency provides a range of services, including patient engagement, relationship marketing, and health behavior consulting, tailored to the needs of pharmaceutical, medical device, and biotechnology companies in the United States. With a strong focus on understanding human health behavior and advocating for healthcare professionals, MicroMass aims to deliver effective solutions that resonate in the healthcare landscape.

Gynecare

Acquisition in 1997
Gynecare offers an endometrial ablation system for the treatment of uterine disorders. Gynecare offers devices like ThermaChoice Uterine Balloon Therapy system for the treatment of women who experience dysfunctional uterine bleeding. It also offers a VersaPoint Bipolar Electrosurgery system to treat women diagnosed with benign uterine pathologies including fibroids, polyps, adhesions, and divided septa.

Mitek Products

Acquisition in 1995
Mitek Surgical Products provided bone anchors and minimally invasive surgical tools for orthopedic surgery. The company was founded by three Massachusetts Institute of Technology engineers in 1985.

Menlo Care

Acquisition in 1994
Menlo Care, Inc. manufactures and markets vascular access and urological devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.